⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27353749 | 0.76 | — | — | |
| SCHEMBL6876381 | 0.74 | — | — | |
| SCHEMBL873901 | 0.70 | — | — | |
| SCHEMBL786087 | 0.70 | — | — | |
| SCHEMBL804785 | 0.70 | ALDH1A1 (0.30) | — | |
| SCHEMBL18881296 | 0.70 | — | — | |
| SCHEMBL636022 | 0.70 | ALDH1A1 (0.33) | — | |
| SCHEMBL23173839 | 0.69 | CA12 (0.46) | — | |
| SCHEMBL13729390 | 0.69 | FFAR3 (0.35) | — | |
| SCHEMBL6864014 | 0.69 | DHFR (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024035950-A1 | INHIBITORS OF KIF18A AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| US-20230365511-A1 | Antiviral Pyrazolopiridinone Compounds | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
| WO-2022268230-A1 | COMPOUND AS KIF18A INHIBITOR | 杭州英创医药科技有限公司 | 2022-12-29 | — | — | WO | disclosed |
| WO-2018081285-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2018-05-03 | — | — | WO | disclosed |
| US-20170267694-A1 | CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND | GILEAD PHARMASSET LLC | 2017-09-21 | — | — | US | disclosed |
| US-20170144971-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-9617310-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20170088583-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2017-03-30 | — | — | US | disclosed |
| US-9562058-B2 | Crystalline forms of an antiviral compound | GILEAD SCIENCES, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-20160137667-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC. (US) | 2016-05-19 | — | — | US | disclosed |
| US-8003659-B2 | Macrocyclic serine protease inhibitors | INDENIX PHARMACEUTICALS, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20110033420-A1 | MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-02-10 | — | — | US | disclosed |
| WO-2010132163-A1 | MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010107384-A1 | ASPARTYL PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2010-09-23 | — | — | WO | disclosed |
| US-7635683-B2 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-20090202480-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090005387-A1 | QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-01-01 | — | — | US | disclosed |
| US-20080032936-A1 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080008681-A1 | MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-01-10 | — | — | US | disclosed |
| US-20070299078-A1 | Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2007-12-27 | — | — | US | disclosed |